Zobrazeno 1 - 10
of 50
pro vyhledávání: '"R. He"'
Autor:
D. Lin, K.A. Wahid, B. Nelms, R. He, M. Naser, S.L. Duke, M. Sherer, M. Cislo, J.D. Murphy, E.F. Gillespie, C.D. Fuller
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:S45-S46
Autor:
K.A. Wahid, B. McDonald, J. Xu, N. O'Connell, N. Cho, D. El-Habashy, S. Ahmed, M. Abobakr, Y. Khamis, A.S. Mohamed, R. He, J. Christodouleas, C.D. Fuller, M. Naser
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:e599-e600
Autor:
Y. Gao, J. Jiang, D. Xiao, Y. Zhou, Y. Chen, H. Yang, L. Wang, J. Zeng, B. He, R. He, Z. Liu, M. Li
Publikováno v:
Journal of Thoracic Oncology. 17:S286-S287
Autor:
K. H. Begna, X. Xu, N. Gangat, H. Alkhateeb, M. M. Patnaik, A. Al-Kali, M. A. Elliott, W. J. Hogan, M. R. Litzow, C. C. Hook, A. P. Wolanskyj-Spinner, A. Mangaonkar, R. He, A. Pardanani, M. Shah, R. P. Ketterling, A. Tefferi
Publikováno v:
Blood Cancer Journal. 12
Autor:
Chao Yin, Monika Kulasekaran, Tina Roy, Brennan Decker, Sonja Alexander, Mathew Margolis, Reena C. Jha, Gary M. Kupfer, Aiwu R. He
Publikováno v:
Cancers; Volume 14; Issue 10; Pages: 2561
Biliary tract cancers (BTCs) are a heterogeneous group of malignancies that make up ~7% of all gastrointestinal tumors. It is notably aggressive and difficult to treat; in fact, >70% of patients with BTC are diagnosed at an advanced, unresectable sta
Autor:
Stephen P. Hack, H. Hochster, Heba Abdullah, Wendy Verret, S. Stein, Aiwu Ruth He, Kazushi Numata, J.W. Lee, Myung-Mook Lee, Baek Yeol Ryoo, Kyung Hun Lee, David P. Ryan, Edward Gane, Masanori Ikeda, A. Dev, Chih-Hung Hsu, Chiun Hsu, N. Sasahira, Jessica Spahn, Amit Mahipal, Y-J. Bang, Yee Chao, Benson M. George, Manabu Morimoto, Niall C. Tebbutt, Michael J. Pishvaian, Michael S. Lee, John H. Strickler, Stacey Stein, K. Numata, Johanna C. Bendell, Gulam Abbas Manji, Yulei Wang, Bo Liu, Aiwu R. He, Ho-Sun Chung, Shukui Qin, Samantha Davis, Jen-Shi Chen, Baek-Yeol Ryoo
Publikováno v:
The Lancet Oncology. 21:808-820
Summary Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone
Autor:
Hongkun Wang, Jimmy J. Hwang, John F. Deeken, Michael J. Pishvaian, Emanuel F. Petricoin, Brandon G. Smaglo, Paula R. Pohlmann, John L. Marshall, Aiwu R. He, Filipa Lynce, Deepa S. Subramaniam
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies. METHODS: Patient
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:S49
Autor:
M. Naser, K.A. Wahid, A. Grossberg, B. Olson, R. Jain, D. El-Habashy, C. Dede, V. Salama, M. Abobakr, A.S. Mohamed, R. He, J. Jaskari, J. Sahlsten, K. Kaski, C.D. Fuller
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:e320
Autor:
D. Lin, K.A. Wahid, B.E. Nelms, R. He, M. Naser, S. Duke, M.V. Sherer, M. Cislo, J.D. Murphy, E.F. Gillespie, C.D. Fuller
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:e11